Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
The senile plaques found within the cerebral cortex and hippocampus of the Alzheimer disease brain contain beta-amyloid peptide (A beta) fibrils that are associated with a variety of macromolecular species, including dermatan sulfate proteoglycan and heparan sulfate proteoglycan.
Why it matters
This laboratory study examined how synthetic amyloid-beta peptides bind to glycosaminoglycans in a pH-dependent way. It is basic biochemistry work and does not test any treatment, cure or prevention for Alzheimer's disease.
-
The GFAP mRNA levels were compared to the density of the senile plaques (SP) in postmortem brain samples of 8 cases, either non-demented or affected by senile dementia of the Alzheimer type.
Why it matters
In postmortem brain samples, GFAP mRNA levels correlated with senile plaque density in the temporal neocortex but not the frontal neocortex. This describes an astrocyte response in Alzheimer disease tissue but does not test any treatment or prevention.
-
It has remained a matter of debate until now whether amyloid and tangle pathology may be regarded as the main causes of the dementia in Alzheimer's disease (AD) or only as markers of the disease.
Why it matters
This study found a diffuse reduction of synapse density in the cortex in Alzheimer's disease, supporting the idea that synapse loss may be a significant factor. It found only a very weak link between amyloid plaque density and synapse staining, and plaque density had no impact in the multivariate analysis.
-
Vulnerability of specific brain regions and neuronal populations is a characteristic feature of Alzheimer disease and Down syndrome.
Why it matters
This study used transplanted fetal brain tissue from trisomy 16 mice, a model of Down syndrome, and found that cholinergic neurons shrank over time. It suggests that hippocampal neurotrophic factors may prevent degeneration, but it is an animal study and does not test a treatment in humans.
-
The amyloid precursor protein (APP) gene codes for the precursor to the beta-protein found in the amyloid deposits of Alzheimer disease (AD).
Why it matters
Testing 76 familial Alzheimer's disease families, 127 sporadic Alzheimer's disease subjects, 16 Down syndrome cases and 256 normal controls found no examples of the APP codon 717 mutation, the APP codon 693 mutation, or the PRIP gene mutations tested. The authors conclude these APP and PRIP mutations are rare in both familial and nonfamilial Alzheimer's disease.
-
The aim of this study was to compare brain glial fibrillary acidic protein (GFAP) levels to the modifications of cognitive functions (Blessed test score [BTS]), the density of the main neuropathological lesions (senile plaques [SP] and neurofibrillary tangles [NFT]), and the density of the two main subtypes of beta A4 deposits (classic plaques and diffuse deposits) in a series of patients with normal aging and senile dementia of the Alzheimer type of various degrees of severity.
Why it matters
In temporal lobe tissue from 12 women over 75, higher levels of glial fibrillary acidic protein correlated with worse cognitive scores and with greater densities of senile plaques, neurofibrillary tangles and classic beta-amyloid plaques. This is a small autopsy study describing a relationship between astrocyte protein and Alzheimer's lesions, not evidence of any treatment, cure or prevention.
-
Previous studies of human hepatic encephalopathy (HE) have shown decreased levels of glial fibrillary acidic protein (GFAP) in Alzheimer type II astrocytes.
Why it matters
Treating rat astrocyte cultures with ammonium chloride for four days caused a 39% loss of GFAP without a fall in total cell protein. This is an early cell-culture finding about a protein change seen in Alzheimer type II astrocytes, not a treatment or prevention result.
-
The activities of red blood cell enzymes that scavenge the superoxide radical and hydrogen peroxide were measured in severely to profoundly retarded adult Down syndrome (DS) patients with and without manifestations of Alzheimer disease (AD), and control individuals matched for sex, age, and time of blood sampling.
Why it matters
This study measured red blood cell antioxidant enzymes and found that Down syndrome patients with Alzheimer manifestations had lower superoxide dismutase levels after adjusting for gene dosage, while glutathione peroxidase was similarly elevated in those with and without Alzheimer manifestations. It reports an association in blood samples only and no treatment effect.
-
We identified by a monoclonal antibody-based immunoradiometric assay high concentrations of an exocrine pancreatic protein called pancreatic thread protein (PTP) in several areas of Alzheimer disease (AD) brain.
Why it matters
A pancreatic protein was found at much higher levels in Alzheimer disease brain tissue than in controls, and was also seen in Down syndrome. This is a postmortem tissue finding and does not test treatment, cure, or prevention.
-
Basal ganglia, cerebral cortex and subcortical white matter were studied for glial fibrillary acidic protein (GFAP) in four cases of hepatic encephalopathy (HE) with Alzheimer II gliosis and five age-matched controls.
Why it matters
In four cases of hepatic encephalopathy, GFAP was decreased by about 70% in the cerebral cortex and 60% in the basal ganglia compared with controls, while white matter GFAP was not significantly changed. This concerns hepatic encephalopathy, not Alzheimer's disease, so it does not directly inform Alzheimer's treatment or prevention.
-
Tau protein misfolding and deposition in the brain is a common factor across many neurodegenerative diseases, grouped under the term tauopathies.
Why it matters
This paper discusses how tau protein misfolds and aggregates in tauopathies, including frontotemporal lobar degeneration, and how tau fragments released from neurons can be measured in cerebrospinal fluid and plasma as biomarkers. It raises the question of whether tau acetylation could be key to diagnosing frontotemporal lobar degeneration, but the text provided does not report a study result or a new treatment for Alzheimer's disease.
-
The majority of the participants met criteria for obesity.
Why it matters
In 188 non-demented adults with Down syndrome, higher BMI was strongly associated with elevated markers of systemic inflammation, while aging and early amyloid burden showed more limited links. The authors emphasize monitoring and weight management to help reduce inflammation, but this cross-sectional study does not test whether that affects Alzheimer's disease onset or progression.
-
Oxidative stress causes brain damage contributing to neurodegenerative and vascular diseases.
Why it matters
In a laboratory triple culture of neurons, astrocytes, and microglia, extracellular vesicles from amniotic fluid stem cells reversed damage caused by LPS and hydrogen peroxide. This is in-vitro research, so it does not yet show a treatment for Alzheimer's disease in people.
-
37/100
The increase in senescent cells, including glial cells in the brain, is a general feature of normal aging and has been associated with age-related pathologies.
Why it matters
This review discusses how aging astrocytes contribute to cognitive decline and notes that targeting astrocytes genetically or pharmacologically may rescue decline in aging and neurodegenerative disease. It is a discussion of emerging evidence, not a proven treatment.
-
37/100
In this study, the rank of multifaceted activity of catechin (C), epicatechin (EC), epigallocatechin (EGC), epicatechin-3-gallate (ECG) and epigallocatechin-3-gallate (EGCG) was addressed.
Why it matters
In laboratory model systems, the catechins EGCG and ECG were the most active at inhibiting acetylcholinesterase and formation of advanced glycation end-products, alongside antioxidant effects. These are in vitro findings relevant to Alzheimer-type dementia, not evidence of benefit in patients.
-
In the AD continuum group, all cognitive test performances significantly correlated with tracer uptake, particularly in the left cortical areas.
Why it matters
This imaging study found that neuropsychological test performance correlated with florzolotau (18F) tracer uptake in patients with tauopathy, with differences between the Alzheimer's disease continuum and non-Alzheimer's tauopathies. It concerns a marker of tau pathology, not a treatment, cure or prevention.
-
Processed foods are increasingly associated with the prevalence of neurodegenerative diseases, including Alzheimer disease (AD).
Why it matters
In Alzheimer's model mice, long-term exposure to carbon-based polymers from processed food accelerated neuroinflammation and synaptic dysfunction through the gut-brain axis. This is animal research, so it does not prove that these food-derived polymers cause or worsen Alzheimer's disease in people.
-
Tauopathies are neurodegenerative diseases characterized by accumulation of hyperphosphorylated tau protein (P-tau).
Why it matters
In P301S tau mice, amitriptyline reduced colonic acid sphingomyelinase and ceramide levels and changed the gut microbiome profile. This is an animal study, so it does not yet show that amitriptyline treats tauopathy in humans.
-
: ACTB: actin, beta; AD: Alzheimer disease; ADAM10: a disintegrin and metallopeptidase domain 10; ADGGA: acyl diacylglyceryl glucuronide; AHexSIS: acylhexosyl sitosterol; AHexSTS: acylhexosyl stigmasterol; AIF1/IBA1: allograft inflammatory factor 1; APP: amyloid beta precursor protein; ATG5: autophagy related 5; Aβ: amyloid β-protein; BACE1: beta-site APP cleaving enzyme 1; BASulfate: bile acid sulfate; BMP: bismonoacylglycerophosphate; CAR: acylcarnitine; CE: cholesteryl ester; Cer_NS: ceramide non-hydroxyfatty acid-sphingosine; CL: cardiolipin; CMA: chaperone-mediated autophagy; DAPI: 4',6-diamidino-2-phenylindole; DCAE: esterified deoxycholic acid; DEP: differentially expressed protein; DG: diacylglycerol; DGCC: diacylglyceryl-3-O-carboxyhydroxymethylcholine; DLG4/PSD95: discs large MAGUK scaffold protein 4; ECM: extracellular matrix; EtherLPC: ether-linked lysophosphatidylcholine; EtherLPE: ether-linked lysophosphatidylethanolamine; EtherMGDG: ether-linked monogalactosyldiacylglycerol; EtherOxPC: ether-linked oxidized phosphatidylcholine; EtherPC: ether-linked phosphatidylcholine; EtherPE: ether-linked phosphatidylethanolamine; EtherPG: ether-linked phosphatidylglycerol; EtherSMGDG: semino lipid; EtherTG: ether-linked triacylglycerol; FA: fatty acyls; FA: free fatty acid; FAHFA: fatty acid ester of hydroxyl fatty acid; FJC: fluoro-Jade C; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GDCAE: esterified glycodeoxycholic acid; GFAP: glial fibrillary acidic protein; GL: glycerolipids; GP: glycerophospholipids; HBMP: hemibismonoacylglycerophosphate; HexCer_NS: hexosylceramide non-hydroxyfatty acid-sphingosine; HSPA8/HSC70: heat shock protein 8; IP-MS: immunoprecipitation-mass spectrometry; KEGG: Kyoto Encyclopedia of Genes and Genomes; LAMP1: lysosomal-associated membrane protein 1; LAMP2A: lysosomal-associated membrane protein 2A; LDGCC: lysodiacylglyceryl-3-O-carboxyhydroxymethylcholine; LDs: lipid droplets; LNAPE: N-acyl-lysophosphatidylethanolamine; LNAPS: N-acyl-lysophosphatidylserine; LPA: lysophosphatidic acid; LPC: lyso-phophatidylcholine; LPE: lysophosphatidylethanolamine; LPG: lysophosphatidylglycerol; LPI: lysophosphatidylinositol; LPS: lysophosphatidylserine; MAP1LC3B/LC3B: microtubule-associated protein 1 light chain 3 beta; MGDG: monogalactosyldiacylglycerol; MWM: Morris Water Maze; OA: oleic acid; OFT: Open Field Test; OxPC: oxidized phosphatidylcholine; OxPG: oxidized phosphatidylglycerol; OxPI: oxidized phosphatidylinositol; OxPS: oxidiz
Why it matters
This study reports that loss of FURIN in the brain impairs astrocytic lipophagy through ITGAV maturation, linking a specific molecular pathway to astrocyte function. It is basic mechanistic work and does not show any treatment, cure or prevention for Alzheimer's disease.
-
Our preliminary results found no significant association between LOAD and the individual SNPs defining the CFH or ARMS2/HTRA1 loci.
Why it matters
Preliminary results found no significant association between late-onset Alzheimer's disease and individual SNPs at the CFH or ARMS2/HTRA1 loci. Examining haplotypes may provide more power to understand the risk these loci confer.
-
Three robustly differentiated AD subtypes (S1, S2, and S3) were identified, with 93% validation accuracy and Adjusted Mutual Information scores >0.89, each exhibiting distinct tau patterns.
Why it matters
A self-supervised deep learning approach identified three AD subtypes with distinct tau-PET patterns and different cognitive deficits, with 93% validation accuracy. This describes disease heterogeneity for classification, not a treatment, cure, or prevention.
-
Three robustly differentiated AD subtypes (S1, S2, and S3) were identified, with 93% validation accuracy and Adjusted Mutual Information scores >0.89, each exhibiting distinct tau patterns.
Why it matters
A self-supervised deep learning approach identified three AD subtypes with distinct tau-PET patterns and different cognitive deficits, with 93% validation accuracy. This describes disease heterogeneity for classification, not a treatment, cure, or prevention.
-
Both taus are very significantly correlated ( p 0,697 in all groups), and with YKL‐40 (r>0.430).
Why it matters
This study examined associations between cerebrospinal fluid YKL-40 and Alzheimer's disease pathology markers, finding stage-specific relationships. It is a biomarker study and does not test or demonstrate any treatment, cure or prevention.
-
Recent evidence indicates the presence of micro- and nanoplastics in the human brain, with higher accumulation observed in patients with dementia.
Why it matters
In human astrocytes grown in the laboratory, polystyrene micro- and nanoplastics caused oxidative stress, inflammation, and impaired glucose metabolism. This is cell research, so it does not show that microplastics cause or worsen Alzheimer's disease in people.
-
HIV-associated neurocognitive disorders (HAND) affect 30%-50% of individuals living with HIV on combination antiretroviral therapy, with Alzheimer 's-like pathology as a potent comorbidity of HAND.
Why it matters
In a humanized mouse model of HIV infection, intranasal delivery of extracellular vesicles carrying HIF-1alpha siRNA reduced Alzheimer's-like pathology including amyloid and tau, and partially restored synaptic proteins. This is an early animal study, and trends of improvement in behavioral deficits were observed, but it does not establish benefit in people with Alzheimer's disease.
From across this topic
10 of the 4,748 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Cross-Sectional and Longitudinal Associations of Neighborhood Disadvantage With Fluid Biomarkers of Neuroinflammation and Neurodegeneration
- The gain-of-function TREM2-T96K mutation increases risk for Alzheimer's disease by impairing microglial function
- Perivascular spaces in the brain: anatomy, physiology and pathology
- The FTD-like syndrome causing TREM2 T66M mutation impairs microglia function, brain perfusion, and glucose metabolism
- 2′-Fucosyllactose mitigates cognitive deficits in Alzheimer models: targeting amyloid pathology, oxidative stress, and synaptic plasticity
- Activation and effective connectivity changes following explicit-memory training for face-name pairs in patients with mild cognitive impairment: a pilot study
- Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice
- Preliminary evidence for sensitive periods in the effect of childhood sexual abuse on regional brain development
- Reduction of chromatin assembly factor 1 p60 and C21orf2 protein, encoded on chromosome 21, in Down syndrome brain
- 18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes